Mr. Batchelder is a life science industry veteran with more than three decades of experience helping shape the strategies of companies and organizations involved in the development of groundbreaking therapeutics. He most recently served as cofounder and chief executive oﬃcer of Civitas Therapeutics, a pulmonary delivery company with a lead program for treating Parkinson’s disease that was acquired by Acorda Therapeutics.
An active member of the life science community, Mr. Batchelder is the chairman of the board of XyloCor Therapeutics and sits on the boards of Synspira, The Michael J. Fox Foundation for Parkinson’s Research, The Possible Project, and MassBio.
Prior to his work with Civitas, Mr. Batchelder was the founding CEO of BIND Therapeutics (BIND), a leading nanotherapeutics company that was acquired by Pﬁzer. Before BIND, he was the initial CEO of Acceleron Pharma, an oncology and supportive care biotherapeutics company. Mr. Batchelder has also served as senior vice president of operations at Millennium Pharmaceuticals, where he played an integral leadership role in the launch of VELCADE® and was responsible for the commercial supply chain and technical operations for INTEGRLIN®.
Mr. Batchhelder received a BS in chemical engineering from Lehigh University.